Kirsten E. Coleman

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “RNA aggregates harness the danger response for potent cancer immunotherapy”.

RNA aggregates harness the danger response for potent cancer immunotherapy

Cell(2024)10.1016/j.cell.2024.04.003

N/A

0.737DataRank · unranked

135 citations

Anna DeVries, Paul Castillo, Christina A. Von Roemeling, Sadeem Qdaisat, Brian Stover +52 more

AAV9 Gene Therapy in GM1 Gangliosidosis Type II: A Phase 1/2 Trial

medRxiv(2025)10.1101/2025.07.28.25332074

N/A

0.212DataRank · unranked

3 citations

Precilla D’Souza, Jean M. Johnston, Maria T. Acosta, Cristan Farmer, Eva H. Baker +27 more

A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system

Molecular Therapy(2021)10.1016/j.ymthe.2021.07.010

N/A

0DataRank · unranked

62 citations

Liudmyla Kondratova, Ronald J. Mandel, Kirsten E. Coleman, Michael A. Savage, Heather Gray‐Edwards +7 more

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies

Journal of Clinical Investigation(2023)10.1172/jci173510

N/A

0DataRank · unranked

135 citations

Manuela Corti, Kirsten E. Coleman, Megan B. Wichman, Julie Berthy, Precilla D’Souza +10 more

Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy

Science Translational Medicine(2023)10.1126/scitranslmed.abo1815

N/A

0DataRank · unranked

68 citations

Michael W. Lawlor, Thomas J. Conlon, Lee‐Jae Guo, Julie M. Crudele, Eleanor C. Hawkins +26 more